COVICEPT THERAPEUTICS
CoviCept Therapeutics is focused on the development of a small molecule that inhibits the replication and spread of RNA viruses.
COVICEPT THERAPEUTICS
Industry:
Biotechnology Life Science Pharmaceutical
Founded:
2020-01-01
Address:
San Diego, California, United States
Country:
United States
Total Employee:
1+
Status:
Active
Total Funding:
2.3 M USD
Similar Organizations
Apic Bio
Apic Bio is a gene therapy company that develops treatment options for rare, undertreated neurological and liver diseases.
Aviceda Therapeutics
Aviceda Therapeutics is a late-stage, pre-clinical biotech company developing drugs for treating glyco-immune diseases.
Castle Creek Biosciences
Castle Creek Biosciences is focused on developing commercializing novel, personalized gene therapies for rare skin disorders.
D2M Biotherapeutics
D2M Biotherapeutics focuses on the development of novel immunotherapeutics.
Orphion Therapeutics
Orphion Therapeutics is focused on the development of novel gene therapies for the treatment of rare and serious genetic disorders.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Syros Pharmaceuticals
Syros Pharmaceuticals is a life sciences company that focuses on treating diseases by mapping gene regulatory circuits.
Current Employees Featured
Founder
Investors List
Forbion Capital Partners
Forbion Capital Partners investment in Seed Round - CoviCept Therapeutics
More informations about "CoviCept Therapeutics"
CoviCept Therapeutics Company Profile 2024: …
CoviCept Therapeutics General Information Description. Developer of small molecule inhibitor of SARS-CoV-2 and other RNA viruses intended to develop the direct therapeutic option to curb the COVID-19 pandemic.See details»
CoviCept Therapeutics - Funding, Financials, Valuation & Investors
CoviCept Therapeutics is focused on the development of a small molecule that inhibits the replication and spread of RNA viruses. Search Crunchbase. Start Free Trial . ... How much …See details»
CoviCept Therapeutics - VentureRadar
"CoviCept Therapeutics, Inc. (“CoviCept”) is a California-based company that is developing a small molecule that inhibits the replication of SARS-CoV-2 (COVID-19) and other RNA viruses.See details»
CoviCept Therapeutics - Products, Competitors, Financials, …
CoviCept Therapeutics develops a small molecule that inhibits the replication of SARS-CoV-2 (COVID-19) and other RNA viruses. Use the CB Insights Platform to explore CoviCept …See details»
CoviCept Therapeutics - Updates, News, Events, Signals & Triggers
Jan 19, 2021 BioWorld Financial Watch — Covicept lands Forbion backing for mission to tackle RNA viruses Funding Round • Jan 19, 2021 CoviCept Therapeutics raised $2,300,000 / Seed …See details»
CoviCept Therapeutics | VentureRadar
Ennaid Therapeutics USA Privately Held Ennaid Therapeutics is a global biopharmaceutical company using its unique, patented platform technology to safely and rapidly develop and …See details»
Forbion invests USD 2.3M in seed financing of CoviCept …
Jan 19, 2021 CoviCept Therapeutics, Inc. is a newly founded company based in San Diego, USA, focused on the development of a small molecule that inhibits the replication and spread …See details»
Forbion Portfolio company Covicept Therapeutics initiates a Phase …
Oct 6, 2021 Naarden, The Netherlands, 6 October 2021 – Forbion, a leading European life sciences venture capital firm, today notes that portfolio company Covicept Therapeutics, Inc. …See details»
Covicept Therapeutics Inc. - BioWorld
Feb 5, 2021 Covicept Therapeutics Inc., a young San Diego-based company focused on developing a small molecule to inhibit the replication and spread of SARS-CoV-2 and other …See details»
Covicept Therapeutics initiates a Phase 2 clinical study with PJS …
San Diego, USA, October 6 th, 2021 – Covicept Therapeutics, an antiviral drug development company, announced today that a double-blind, placebo-controlled Phase 2 trial of PSJ-539 …See details»
CoviCept Therapeutics - Contacts, Employees, Board Members
CoviCept Therapeutics has 3 current employee profiles, including Co-Founder, Chairman & Chief Executive Officer Sam Tsimikas. Sam Tsimikas Co-Founder, Chairman & Chief Executive …See details»
Development of a small molecule that inhibits the replication of …
Jan 22, 2021 Forbion, a European life sciences venture capital firm, announces a $2.3m seed investment in newly formed CoviCept Therapeutics, Inc., a California-based company that is …See details»
PJS 539 - AdisInsight - Springer
04 Mar 2022 Covicept Therapeutics completes a phase-II clinical trial in COVID-2019 infections (In adults) in Brazil (PO) (NCT05008393) ... If your organization or you do not have a …See details»
Covicept Therapeutics initiates a Phase 2 clinical study
Oct 6, 2021 Covicept Therapeutics, Inc. was founded in 2020 in San Diego, California USA, based on discoveries by Professor Sam Tsimikas, Professor Philip Gordts and Professor …See details»
Covicept lands Forbion backing for mission to tackle RNA viruses
Feb 5, 2021 Covicept Therapeutics Inc., a young San Diego-based company focused on developing a small molecule to inhibit the replication and spread of SARS-CoV-2 and other …See details»
Covicept commences Phase II oral Covid-19 drug trial in Brazil
Oct 7, 2021 Covicept Therapeutics co-founder, chairman and CEO professor Sam Tsimikas: “It is a significant milestone for this programme to move into clinical development in less than a …See details»
CoviCept Therapeutics - Crunchbase
CoviCept Therapeutics is focused on the development of a small molecule that inhibits the replication and spread of RNA viruses. Search Crunchbase. Start Free Trial . Chrome …See details»
PJS-539 - Drug Targets, Indications, Patents - Synapse
Originator Organization. University of California San Diego. ... Covicept Therapeutics, Inc. Startup. Drug Highest Phase Pending Phase 2. First Approval Date-Regulation-Login to view timeline. …See details»
Roberto Vieira - Corcept Therapeutics
Mr. Vieira joined Corcept as President of Oncology in January 2024. He brings more than 20 years of sales, marketing, and oncology experience to his role. Mr. Vieira previously served as …See details»